The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate privosegtor (formerly known as OCS-05) for the treatment of optic neuritis (ON). 1 ...
Swiss biotech Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of encouraging phase 2 data. The Zug-based company said ...
Oculis Holding AG (OCS) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 4:30 PM ESTCompany ParticipantsRiad Sherif - CEO ...
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate ...
8 Research Institute for Sport and Exercise Science, Liverpool John Moores University, Liverpool, UK Correspondence to Mathew Wilson, Research Centre for Sport and Exercise Performance, School of ...
Primary angle-closure glaucoma can cause blindness. Here, the authors study populations of Asian and European ancestries and find that genetic factors associated with darker irises and being far ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback